NYSE:DPLO - Diplomat Pharmacy Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$5.41 +0.20 (+3.84 %)
(As of 04/21/2019 03:06 PM ET)
Previous Close$5.41
Today's Range$5.21 - $5.44
52-Week Range$4.99 - $28.74
Volume571,571 shs
Average Volume962,158 shs
Market Capitalization$402.99 million
P/E Ratio27.05
Dividend YieldN/A
Beta0.72
Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems. The company primarily focuses on medication management programs for individuals with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious or long-term conditions. It also offers PBM services, including electronic point-of-sale pharmacy claims management, retail pharmacy network management, mail pharmacy claims management, specialty pharmacy claims management, Medicare Part D services, benefit design consultation, drug review and analysis, consulting services, data access, and reporting, information analysis, and preferred drug management programs to managed care organizations, self-insured employer groups, unions, and third-party healthcare plan administrators and worker's compensation payers. The company was founded in 1975 and is headquartered in Flint, Michigan.

Receive DPLO News and Ratings via Email

Sign-up to receive the latest news and ratings for DPLO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug stores & proprietary stores
Sub-IndustryN/A
SectorRetail/Wholesale
CUSIPN/A
Phone888-720-4450

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.49 billion
Cash Flow$4.5847 per share
Book Value$6.24 per share

Profitability

Net Income$-302,270,000.00

Miscellaneous

Employees2,335
Market Cap$402.99 million
Next Earnings Date5/7/2019 (Confirmed)
OptionableOptionable

Diplomat Pharmacy (NYSE:DPLO) Frequently Asked Questions

What is Diplomat Pharmacy's stock symbol?

Diplomat Pharmacy trades on the New York Stock Exchange (NYSE) under the ticker symbol "DPLO."

How were Diplomat Pharmacy's earnings last quarter?

Diplomat Pharmacy Inc (NYSE:DPLO) announced its quarterly earnings results on Friday, March, 15th. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.24 by $0.10. The company had revenue of $1.36 billion for the quarter, compared to analyst estimates of $1.41 billion. Diplomat Pharmacy had a negative net margin of 5.50% and a positive return on equity of 5.51%. Diplomat Pharmacy's revenue was up 17.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.09 earnings per share. View Diplomat Pharmacy's Earnings History.

When is Diplomat Pharmacy's next earnings date?

Diplomat Pharmacy is scheduled to release their next quarterly earnings announcement on Tuesday, May 7th 2019. View Earnings Estimates for Diplomat Pharmacy.

How can I listen to Diplomat Pharmacy's earnings call?

Diplomat Pharmacy will be holding an earnings conference call on Tuesday, May 7th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8332865805.

What guidance has Diplomat Pharmacy issued on next quarter's earnings?

Diplomat Pharmacy issued an update on its FY19 earnings guidance on Friday, March, 15th. The company provided earnings per share (EPS) guidance of ($0.50-0.34) for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.18). The company issued revenue guidance of $4.7-5.0 billion, compared to the consensus revenue estimate of $5.51 billion.Diplomat Pharmacy also updated its FY 2019 guidance to $-0.5-0.34 EPS.

What price target have analysts set for DPLO?

13 analysts have issued 12 month target prices for Diplomat Pharmacy's shares. Their predictions range from $6.00 to $30.00. On average, they expect Diplomat Pharmacy's stock price to reach $10.4167 in the next twelve months. This suggests a possible upside of 92.5% from the stock's current price. View Analyst Price Targets for Diplomat Pharmacy.

What is the consensus analysts' recommendation for Diplomat Pharmacy?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Diplomat Pharmacy in the last year. There are currently 2 sell ratings, 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Diplomat Pharmacy.

Has Diplomat Pharmacy been receiving favorable news coverage?

Press coverage about DPLO stock has trended neutral on Sunday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Diplomat Pharmacy earned a news impact score of 0.4 on InfoTrie's scale. They also gave headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future.

Who are some of Diplomat Pharmacy's key competitors?

What other stocks do shareholders of Diplomat Pharmacy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diplomat Pharmacy investors own include Bausch Health Companies (BHC), General Electric (GE), Gilead Sciences (GILD), Activision Blizzard (ATVI), XOMA (XOMA), Cannabis Sativa (CBDS), Netflix (NFLX), Alibaba Group (BABA), CVS Health (CVS) and Adamis Pharmaceuticals (ADMP).

Who are Diplomat Pharmacy's key executives?

Diplomat Pharmacy's management team includes the folowing people:
  • Mr. Philip R. Hagerman, Co-Founder & Chairman Emeritus (Age 67)
  • Mr. Gary Rice M.B.A., M.S., R.Ph., RPh, MS, MBA, CSP, Exec. VP of Operations (Age 61)
  • Mr. Brian Thomas Griffin, CEO & Chairman (Age 60)
  • Mr. Daniel Paul Davison, CFO & Treasurer
  • Mr. Dave Loschinskey, Chief Information Officer

How do I buy shares of Diplomat Pharmacy?

Shares of DPLO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Diplomat Pharmacy's stock price today?

One share of DPLO stock can currently be purchased for approximately $5.41.

How big of a company is Diplomat Pharmacy?

Diplomat Pharmacy has a market capitalization of $402.99 million and generates $5.49 billion in revenue each year. The company earns $-302,270,000.00 in net income (profit) each year or $0.20 on an earnings per share basis. Diplomat Pharmacy employs 2,335 workers across the globe.

What is Diplomat Pharmacy's official website?

The official website for Diplomat Pharmacy is http://www.diplomatpharmacy.com.

How can I contact Diplomat Pharmacy?

Diplomat Pharmacy's mailing address is 4100 S. SAGINAW ST., FLINT MI, 48507. The company can be reached via phone at 888-720-4450 or via email at [email protected]


MarketBeat Community Rating for Diplomat Pharmacy (NYSE DPLO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  303 (Vote Outperform)
Underperform Votes:  323 (Vote Underperform)
Total Votes:  626
MarketBeat's community ratings are surveys of what our community members think about Diplomat Pharmacy and other stocks. Vote "Outperform" if you believe DPLO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DPLO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel